TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Medical · Reference only · no online purchase

Rozerem (Ramelteon)

Rozerem / Ramelteon. Used to improve difficulty falling asleep in insomnia.

PMDAproduct-level source2026-09label updated2026-10-05site verified
ロゼレム錠8mg · 8 mg
Japanese product photo · 8 mg · 松岡明芳 / CC BY-SA 4.0
Main useUsed to improve difficulty falling asleep in insomnia.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
ロゼレム錠8mg
Brand
Rozerem
Generic name
Ramelteon
Japanese generic name
ラメルテオン
Chinese name
雷美替胺
Marketing authorization holder
武田薬品工業株式会社
Strengths
8 mg
Dosage form
tablet
Therapeutic area
Neurology
Regulatory status
Medical
Label updated
2026-09
TOKYO MEDI verified
2026-10-05
Regulatory status note

Prescription-only designation removed in September 2026; still listed by PMDA as a medical-use medicine.

MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Rozerem is an 8 mg melatonin-receptor agonist, distinct from benzodiazepines, Z-drugs and melatonin supplements.

Read source section ↗
02

Mechanism of action

Acts at MT1/MT2 melatonin receptors rather than primarily at GABA-A receptors.

Read source section ↗
03

Japanese indications & eligibility

Japanese use is insomnia-related sleep-onset difficulty. The prescription-only designation changed in September 2026; it remains a medical-use medicine.

Read source section ↗
04

Administration & dose differences

Usually 8 mg before bedtime; avoid taking with/immediately after a meal and prepare to sleep.

Read source section ↗
05

Adverse effects & key risks

Somnolence, dizziness and fatigue can impair next-day activities; persistent insomnia requires reassessment.

Read source section ↗
06

Contraindications & special populations

Contraindicated with severe hepatic impairment, hypersensitivity or fluvoxamine use.

Read source section ↗
07

Drug interactions

Fluvoxamine is contraindicated; review CYP modifiers, sedatives and alcohol.

Read source section ↗
08

Assessment & monitoring

Track sleep onset, routine, daytime sedation and medication/alcohol use.

Read source section ↗
09

Storage & handling

Store at room temperature in original packaging; the photo is the Japanese 8 mg blister.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.